Literature DB >> 21325555

Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype.

S W Satola1, F C Lessa, S M Ray, S N Bulens, R Lynfield, W Schaffner, G Dumyati, J Nadle, J B Patel.   

Abstract

We describe clinical and laboratory characteristics of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections with vancomycin MICs of 2 μg/ml and compare heteroresistant-intermediate S. aureus (hVISA) to non-hVISA. Health care-associated community-onset infections were the most common and resulted in frequent complications and relapses. hVISA-infected patients were more likely to have been hospitalized in the year prior to MRSA culture.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325555      PMCID: PMC3122783          DOI: 10.1128/JCM.01719-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

2.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

3.  Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer
Journal:  Int J Antimicrob Agents       Date:  2008-08-12       Impact factor: 5.283

4.  Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.

Authors:  Jana M Swenson; Karen F Anderson; David R Lonsway; Angela Thompson; Sigrid K McAllister; Brandi M Limbago; Roberta B Carey; Fred C Tenover; Jean B Patel
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

5.  Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis.

Authors:  Brandi Limbago; Gregory E Fosheim; Valerie Schoonover; Christina E Crane; Joelle Nadle; Susan Petit; David Heltzel; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Yi Mu; Scott K Fridkin
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

6.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

7.  Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

Authors:  K C Horne; B P Howden; E A Grabsch; M Graham; P B Ward; S Xie; B C Mayall; P D R Johnson; M L Grayson
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

8.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Authors:  Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

9.  Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.

Authors:  Adina C Musta; Kathleen Riederer; Stephen Shemes; Patrick Chase; Jinson Jose; Leonard B Johnson; Riad Khatib
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

10.  Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

Authors:  Yasmin Maor; Michal Hagin; Natasha Belausov; Nathan Keller; Debbi Ben-David; Galia Rahav
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

View more
  8 in total

1.  Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Davida S Smyth; Bo Shopsin; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

2.  Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.

Authors:  Jasmine Chong; Caroline Quach; Ana C Blanchard; Philippe Guillaume Poliquin; George R Golding; Céline Laferrière; Simon Lévesque
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Clinico-microbiological study and antibiotic resistance profile of mecA and ESBL gene prevalence in patients with diabetic foot infections.

Authors:  Waqas Nasir Chaudhry; Rabia Badar; Muhsin Jamal; Jason Jeong; Jamal Zafar; Saadia Andleeb
Journal:  Exp Ther Med       Date:  2016-01-14       Impact factor: 2.447

4.  Clinical and Molecular Characterization of Invasive Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Infections in Korean Hospitals.

Authors:  Eu Suk Kim; In-Gyu Bae; Jeong Eun Cho; Yun Jung Choi; Il-Hwan Kim; Gi-Su Kang; Hye-yun Sin; Kyoung-Ho Song; Chulmin Park; Dong-Gun Lee; Moonsuk Kim; Kyoung Un Park; Hong Bin Kim
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

5.  Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  So-Youn Park; In-Hwan Oh; Hee-Joo Lee; Chun-Gyoo Ihm; Jun Seong Son; Mi Suk Lee; Mi-Na Kim
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

6.  Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.

Authors:  Md Tauqeer Alam; Robert A Petit; Emily K Crispell; Timothy A Thornton; Karen N Conneely; Yunxuan Jiang; Sarah W Satola; Timothy D Read
Journal:  Genome Biol Evol       Date:  2014-04-30       Impact factor: 3.416

Review 7.  Treatment of Gram-positive infections in critically ill patients.

Authors:  Cristina Vazquez-Guillamet; Marin H Kollef
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

8.  Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil.

Authors:  Alessandro Conrado de Oliveira Silveira; Gabriela Rosa da Cunha; Juliana Caierão; Caio Mauricio Mendes de Cordova; Pedro Alves d'Azevedo
Journal:  Braz J Infect Dis       Date:  2015-08-21       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.